share_log

Keybanc Maintains Overweight on Avid Bioservices, Lowers Price Target to $14

Benzinga ·  Dec 8, 2023 04:22

Keybanc analyst Paul Knight maintains Avid Bioservices (NASDAQ:CDMO) with a Overweight and lowers the price target from $20 to $14.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment